13F-HR: Pfizer Discloses Q3 2025 Equity Holdings

Pfizer Inc. filed its Form 13F-HR, revealing its equity holdings totaling over $437 million as of September 30, 2025.

Summary

• Pfizer Inc. filed a Form 13F Holdings Report for the calendar quarter ended September 30, 2025.
• The report details 24 distinct equity holdings.
• The total market value of these reported holdings is $437,450,705.
• The portfolio primarily consists of common stock and sponsored ADS in biotechnology and pharmaceutical companies.

Sentiment

Score: 5

Explanation: The filing is a routine, factual disclosure of equity holdings and does not contain performance metrics, forward-looking statements, or qualitative information that would indicate a positive or negative sentiment regarding Pfizer's operational performance or future prospects.

Positives

• Manages a substantial equity portfolio with a total reported value of $437,450,705, indicating active investment management.

Future Outlook

NA

Industry Context

This filing reflects Pfizer's investment activities within the broader life sciences sector, specifically targeting biotechnology and pharmaceutical companies. Such investments are common for large pharmaceutical firms looking to gain exposure to innovation, potential future therapies, or strategic partnerships within their core industry.

Comparison to Industry Standards

• The portfolio's concentration in biotechnology and pharmaceutical companies is consistent with a strategic investor like Pfizer, aligning with its core business and potential R&D interests.
• The mix of holdings, including both established and emerging companies (e.g., BIONTECH SE, ALLOGENE THERAPEUTICS INC, ZENTALIS PHARMACEUTICALS INC), suggests a diversified approach within its sector focus.

Stakeholder Impact

• Shareholders: Provides transparency into Pfizer's equity investment strategy and the composition of its investment portfolio.
• Investment Professionals: Offers insights into Pfizer's investment decisions and sector focus within the biotechnology and pharmaceutical industries.

Key Dates

Recommendation

This Form 13F-HR is a routine quarterly disclosure of Pfizer Inc.'s equity holdings as an institutional investment manager. It provides a snapshot of its investment portfolio as of September 30, 2025, but does not contain information regarding Pfizer's own operational performance, financial results, or future guidance. As such, this specific filing does not introduce new fundamental data that would warrant a change in the investment recommendation for Pfizer's stock. Investors should 'hold' based on this disclosure, awaiting more comprehensive financial reports for performance-based investment decisions.

Keywords

Pfizer, 13F, Holdings Report, Institutional Investment, Equity Portfolio, Biotechnology, Pharmaceuticals, SEC Filing, Q3 2025